By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > Sulfonylurea > Glibenclamide

Glibenclamide

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|633 words

What is Glibenclamide?

Glibenclamide is an oral antidiabetic medication that belongs to the sulfonylurea class of drugs. It is primarily used to treat type 2 diabetes mellitus by helping to lower blood glucose levels. This medication is effective only in patients who still have some functioning pancreatic beta cells that can produce insulin.

Uses

Glibenclamide has several documented medical uses:

  • Type 2 diabetes mellitus: The primary use is as a second-line treatment for type 2 diabetes when diet and exercise alone are insufficient to control blood sugar levels.
  • Combination therapy: Often used alongside other antidiabetic medications such as metformin to achieve better glucose control.
  • Gestational diabetes: In some countries, it may be prescribed for gestational diabetes when insulin therapy is not preferred or available.
  • Neonatal diabetes: Used in certain forms of neonatal diabetes caused by specific genetic mutations affecting potassium channels.
  • Bridge therapy: Sometimes employed as a temporary measure while transitioning patients between different diabetes treatment regimens.

How it works

Glibenclamide works by binding to specific receptors on pancreatic beta cells called sulfonylurea receptors, which are part of ATP-sensitive potassium channels. This binding causes these channels to close, leading to depolarization of the cell membrane and subsequent opening of calcium channels. The influx of calcium triggers the release of insulin from the beta cells, thereby lowering blood glucose levels.

Side effects

Common side effects include:

Submit Your Paper
GMJ_Submit_Banner
  • Hypoglycemia (low blood sugar)
  • Weight gain
  • Nausea and stomach upset
  • Diarrhea or constipation
  • Dizziness
  • Headache
  • Skin rash or itching
  • Increased appetite

Serious side effects to watch for:

  • Severe hypoglycemia with confusion, seizures, or loss of consciousness
  • Severe allergic reactions including difficulty breathing or swelling
  • Blood disorders such as low white blood cell or platelet counts
  • Liver problems indicated by yellowing of skin or eyes
  • Severe skin reactions including Stevens-Johnson syndrome

Warnings and precautions

  • Kidney and liver impairment: Patients with severe kidney or liver disease should avoid glibenclamide as it may accumulate and cause prolonged hypoglycemia.
  • Elderly patients: Older adults are at higher risk for hypoglycemia and should be monitored closely, often requiring lower doses.
  • Pregnancy and breastfeeding: Generally not recommended during pregnancy as insulin is preferred; may pass into breast milk and affect nursing infants.
  • Surgery and stress: May need temporary discontinuation during major surgery, severe infections, or other stressful conditions when insulin requirements change rapidly.
  • Alcohol consumption: Can increase the risk of hypoglycemia and should be limited or avoided, especially on an empty stomach.

Interactions

Several medications and substances can interact with glibenclamide:

  • Warfarin and anticoagulants: May enhance anticoagulant effects, requiring closer monitoring of bleeding risk.
  • Beta-blockers: Can mask symptoms of hypoglycemia and prolong recovery from low blood sugar episodes.
  • Fluconazole and antifungals: May increase glibenclamide levels and risk of hypoglycemia by inhibiting metabolism.
  • Rifampin: Can reduce glibenclamide effectiveness by increasing its metabolism.
  • ACE inhibitors: May enhance glucose-lowering effects and increase hypoglycemia risk.
  • Alcohol: Significantly increases risk of severe hypoglycemia, especially when consumed without food.
  • Aspirin and salicylates: High doses can enhance hypoglycemic effects.
  • Gemfibrozil: Can significantly increase glibenclamide blood levels and hypoglycemia risk.

Check interactions with the GMJ Interaction Checker

Dosage

For adults with type 2 diabetes, the typical starting dose is 2.5 to 5 mg once daily, usually taken with breakfast or the first main meal. The dose may be gradually increased by 2.5 mg every 1-2 weeks based on blood glucose response, up to a maximum of 15-20 mg daily. Some patients may benefit from divided doses taken twice daily to minimize hypoglycemia risk. Dosage adjustments should always be made under medical supervision, with regular monitoring of blood glucose levels. Elderly patients typically start with lower doses due to increased sensitivity and slower drug clearance.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Glibenclamide." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/glibenclamide/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
UK Public Health Laboratory in Birmingham Releases Updated User Handbook for NHS Services

The UK Health Security Agency has released an updated user handbook for…

UK Health Security Agency Launches Evidence-Based Training Programme for Healthcare Staff

The UK Health Security Agency has launched a structured training programme to…

Two Words, One Sector: Why STAT News Keeps ‘Health Care’ Separate

STAT News formalizes editorial convention to maintain 'health care' as two words,…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Glipizide

By
Prof. Giorgi Pkhakadze
02/06/2026

Gliclazide

By
Prof. Giorgi Pkhakadze
02/06/2026

Glimepiride

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up